Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
DUBLIN, Ireland, May 02, 2017 -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the first quarter of 2017 on May 9, 2017 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 9.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company establishing fully-integrated research, development and commercial capabilities. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena seeks to fundamentally change the course of progressive diseases associated with this biology. The Company’s pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002/RG7935), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). The Company continues discovery of additional novel therapeutic candidates where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the Company’s website at www.prothena.com.
Contacts: Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose, Head of Communications 650-922-2405, [email protected]
